Viken – September 26, 2023 – Swedish biopharmaceutical company TikoMed AB today announced the appointment of Caroline Ingre, MD, PhD senior consultant neurology and Head of ALS at Karolinska University Hospital and Karolinska Institute as the second member of its newly-formed Scientific Advisory Board.
Dr. Ingre runs the ALS clinic at Karolinska University Hospital and has created the National ALS/MND Registry in Sweden and the Karolinska Clinical Trial Center, a national center focused solely on ALS clinical trials. She is a board member of TRICALS, the largest European research initiative to find a cure for ALS to date, and also leads several international collaborative projects and trials.
“We are excited to welcome Dr. Ingre to join our SAB,” said Adam Bruce, Founder, Chairman of the Board and CEO, of TikoMed. “Caroline is a world renowned clinical and scientific thought leader. We look forward to her providing TikoMed with informed counsel in the months and years ahead, as we further our clinical efforts with our drug candidate ILB for treatment of ALS.”
“I am delighted to join TikoMed’s SAB at this exciting time for both ALS research in general and ILB in particular. I hope my extensive clinical development and trials experience can be utilized to the benefit of patients suffering from this devasting disease,” commented Dr. Ingre.
The SAB will advise management as Phase 2 clinical development of ILB progresses. The board will integrate highly experienced clinicians as well as seasoned industrial scientific leaders in the field.
Caroline Ingre
Researcher Caroline Ingre is an Associate Professor and Research Group Leader, ALS, at the Department of Clinical Neuroscience at Karolinska Institutet. She is a specialist in neuromuscular disease and has been working in the ALS field for more than 15 years.
Caroline has initiated several collaborations between Universities and University Hospitals in Sweden and hosts both the national clinical ALS meeting and next year’s European ALS meeting, ENCALS. She also leads an ALS research group at Karolinska Institute with main interests in epidemiology, risk and prognosis of ALS disease, the development of imaging methods and biomarker studies, as well as manages several clinical trials in ALS.
Contact
Adam Bruce, Founder, Chairman of the Board and CEO of TikoMed
Email: adam.bruce@tikomed.com.
TikoMed AB
TikoMed is committed to improve human life by exploring and harnessing the medical potential of the body’s ability to self-repair and regenerate. With an adaptive, multi-modal mechanism of action, TikoMed’s drug platform has the potential to rebalance the body’s inflammatory, immune and fibrotic responses to acute and chronic inflammation to enhance self-repair and regeneration.
TikoMed’s initial development programs include Amyotrophic Lateral Sclerosis (ALS), Traumatic Brain Injury (TBI) and islet cell transplantation.
TikoMed’s highly scalable proprietary technology aims to provide innovative medicines to as many patients as possible across the globe.
TikoMed is privately-owned and based in Viken, Sweden. To learn more, visit www.tikomed.com